Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide

The data presented here demonstrate the feasibility of performing SPECT/CT BTV dose escalation in a mature series.